Advertisement

Chirurgie optimale des stades avancés : aspects oncologiques

  • P.-E. Colombo
  • P. Rouanet
Part of the Abord clinique book series (ONCOLPRAT)

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Meigs J (1934) Tumors of the Female Pelvic Organs. New York, Macmillan, 262–3Google Scholar
  2. 2.
    Griffiths CT, Parker LM, Fuller AF, Jr (1979) Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treat Rep 63: 235–40PubMedGoogle Scholar
  3. 3.
    Griffiths CT, Fuller AF (1978) Intensive surgical and chemotherapeutic management of advanced ovarian cancer. Surg Clin North Am 58: 131–42PubMedGoogle Scholar
  4. 4.
    Griffiths CT (1975) Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 42: 101–4PubMedGoogle Scholar
  5. 5.
    Hacker NF, Berek JS, Lagasse LD et al. (1983) Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 61: 413–20PubMedGoogle Scholar
  6. 6.
    Pohl R, Dallenbach-Hellweg G, Plugge T, Czernobilsky B (1984) Prognostic parameters in patients with advanced ovarian malignant tumors. Eur J Gynaecol Oncol 5: 160–9PubMedGoogle Scholar
  7. 7.
    Delgado G, Oram DH, Petrilli ES (1984) Stage III epithelial ovarian cancer: the role of maximal surgical reduction. Gynecol Oncol 18: 293–8CrossRefPubMedGoogle Scholar
  8. 8.
    Neijt JP, Bokkel Huinink WW, van der Burg ME et al. (1987) Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. J Clin Oncol 5: 1157–68PubMedGoogle Scholar
  9. 9.
    Seifer DB, Kennedy AW, Webster KD et al. (1988) Outcome of primary cytoreduction surgery for advanced epithelial ovarian carcinoma. Cleve Clin J Med 55: 555–60PubMedGoogle Scholar
  10. 10.
    Piver MS, Lele SB, Marchetti DL et al. (1988) The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma. J Clin Oncol 6: 983–9PubMedGoogle Scholar
  11. 11.
    Sutton GP, Stehman FB, Einhorn LH et al. (1989) Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma. J Clin Oncol 7: 223–9PubMedGoogle Scholar
  12. 12.
    Bertelsen K (1990) Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study. Gynecol Oncol 38: 203–9CrossRefPubMedGoogle Scholar
  13. 13.
    Del Campo JM, Felip E, Rubio D et al. (1994) Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment. Gynecol Oncol 53: 27–32PubMedGoogle Scholar
  14. 14.
    Hoskins WJ, McGuire WP, Brady MF et al. (1994) The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 170: 974–9PubMedGoogle Scholar
  15. 15.
    Makar AP, Baekelandt M, Trope CG et al. (1995) The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol 56: 175–80CrossRefPubMedGoogle Scholar
  16. 16.
    Scarabelli C, Gallo A, Franceschi S et al. (2000) Primary cytoreductive surgery with rectosigmoid colon resection for patients with advanced epithelial ovarian carcinoma. Cancer 88: 389–97CrossRefPubMedGoogle Scholar
  17. 17.
    Chi DS, Liao JB, Leon LF et al. (2001) Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol 82: 532–7CrossRefPubMedGoogle Scholar
  18. 18.
    Tingulstad S, Skjeldestad FE, Halvorsen TB, Hagen B (2003) Survival and prognostic factors in patients with ovarian cancer. Obstet Gynecol 101: 885–91CrossRefPubMedGoogle Scholar
  19. 19.
    Goldie JH, Coldman AJ (1979) A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63: 1727–33PubMedGoogle Scholar
  20. 20.
    Eisenkop SM, Friedman RL, Wang HJ (1998) Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol 69: 103–8CrossRefPubMedGoogle Scholar
  21. 21.
    Alberts DS, Liu PY, Hannigan EV et al. (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335: 1950–5CrossRefPubMedGoogle Scholar
  22. 22.
    Brun JL, Feyler A, Chene G et al. (2000) Long-term results and prognostic factors in patients with epithelial ovarian cancer. Gynecol Oncol 78: 21–7CrossRefPubMedGoogle Scholar
  23. 23.
    Eisenkop SM, Spirtos NM, Friedman RL et al. (2003) Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol 90: 390–6CrossRefPubMedGoogle Scholar
  24. 24.
    Allen DG, Heintz AP, Touw FW (1995) A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary. Eur J Gynaecol Oncol 16: 349–56PubMedGoogle Scholar
  25. 25.
    Bristow RE, Tomacruz RS, Armstrong DK et al. (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20: 1248–59CrossRefPubMedGoogle Scholar
  26. 26.
    Eitan R, Levine DA, Abu-Rustum N et al. (2005) The clinical significance of malignant pleural effusions in patients with optimally debulked ovarian carcinoma. CancerGoogle Scholar
  27. 27.
    Liu PC, Benjamin I, Morgan MA et al. (1997) Effect of surgical debulking on survival in stage IV ovarian cancer. Gynecol Oncol 64: 4–8CrossRefPubMedGoogle Scholar
  28. 28.
    Munkarah AR, Hallum AV, Morris M et al. (1997) Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer. Gynecol Oncol 64: 13–7CrossRefPubMedGoogle Scholar
  29. 29.
    Bristow RE, Montz FJ, Lagasse LD et al. (1999) Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 72: 278–87CrossRefPubMedGoogle Scholar
  30. 30.
    Curtin JP, Malik R, Venkatraman ES et al. (1997) Stage IV ovarian cancer: impact of surgical debulking. Gynecol Oncol 64: 9–12CrossRefPubMedGoogle Scholar
  31. 31.
    Eisenkop SM, Spirtos NM (2001) What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer? Gynecol Oncol 82: 489–97PubMedGoogle Scholar
  32. 32.
    Eisenkop SM, Spirtos NM, Montag TW et al. (1992) The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol Oncol 47: 203–9CrossRefPubMedGoogle Scholar
  33. 33.
    Covens AL (2000) A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol Oncol 78: 269–74CrossRefPubMedGoogle Scholar
  34. 34.
    Hoskins WJ, Bundy BN, Thigpen JT, Omura GA (1992) The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 47: 159–66CrossRefPubMedGoogle Scholar
  35. 35.
    Hunter RW, Alexander ND, Soutter WP (1992) Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis? Am J Obstet Gynecol 166: 504–11PubMedGoogle Scholar
  36. 36.
    Morice P, Brehier-Ollive D, Rey A et al. (2003) Results of interval debulking surgery in advanced stage ovarian cancer: an exposed-non-exposed study. Ann Oncol 14: 74–7PubMedGoogle Scholar
  37. 37.
    Spirtos NM, Gross GM, Freddo JL, Ballon SC (1995) Cytoreductive surgery in advanced epithelial cancer of the ovary: the impact of aortic and pelvic lymphadenectomy. Gynecol Oncol 56: 345–52CrossRefPubMedGoogle Scholar
  38. 38.
    Le T, Krepart GV, Lotocki RJ, Heywood MS (1997) Does debulking surgery improve survival in biologically aggressive ovarian carcinoma? Gynecol Oncol 67: 208–14CrossRefPubMedGoogle Scholar
  39. 39.
    Eisenkop SM, Spirtos NM (2001) Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with “biological aggressiveness” and survival? Gynecol Oncol 82: 435–41PubMedGoogle Scholar
  40. 40.
    van der Burg ME, van Lent M, Buyse M et al. (1995) The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 332: 629–34PubMedGoogle Scholar
  41. 41.
    Vergote I, De W, I, Tjalma W et al. (1998) Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol 71: 431–6CrossRefPubMedGoogle Scholar
  42. 42.
    Schwartz PE, Rutherford TJ, Chambers JT et al. (1999) Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecol Oncol 72: 93–9CrossRefPubMedGoogle Scholar
  43. 43.
    Kuhn W, Rutke S, Spathe K et al. (2001) Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer 92: 2585–91CrossRefPubMedGoogle Scholar
  44. 44.
    Kayikcioglu F, Kose MF, Boran N et al. (2001) Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma. International Journal of Gynecological Cancer 11: 466–70PubMedGoogle Scholar
  45. 45.
    Fanfani F, Ferrandina G, Corrado G et al. (2003) Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO stage IIIc ovarian cancer patients. Oncology 65: 316–22CrossRefPubMedGoogle Scholar
  46. 46.
    Ansquer Y, Leblanc E, Clough K et al. (2001) Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study. Cancer 91: 2329–34CrossRefPubMedGoogle Scholar
  47. 47.
    Mazzeo F, Berliere M, Kerger J et al. (2003) Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer. Gynecol Oncol 90: 163–9CrossRefPubMedGoogle Scholar
  48. 48.
    Rose PG, Nerenstone S, Brady MF et al. (2004) Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 351: 2489–97CrossRefPubMedGoogle Scholar
  49. 49.
    Chi DS, Venkatraman ES, Masson V, Hoskins WJ (2000) The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol Oncol 77: 227–31CrossRefPubMedGoogle Scholar
  50. 50.
    Vergote IB, De W, I, Decloedt J et al. (2000) Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer. Semin Oncol 27: 31–6PubMedGoogle Scholar
  51. 51.
    Friedman RL, Eisenkop SM, Wang HJ (1997) Second-look laparotomy for ovarian cancer provides reliable prognostic information and improves survival. Gynecol Oncol 67: 88–94CrossRefPubMedGoogle Scholar
  52. 52.
    Clough KB, Ladonne JM, Nos C et al. (1999) Second look for ovarian cancer: laparoscopy or Laparotomy? A prospective comparative study. Gynecol Oncol 72: 411–7CrossRefPubMedGoogle Scholar
  53. 53.
    Ozalp S, Yalcin OT, Dundar E et al. (1999) Second-look laparotomy; factors affecting the results and the prognosis. Eur J Gynaecol Oncol 20: 398–402PubMedGoogle Scholar
  54. 54.
    Hempling RE, Wesolowski JA, Piver MS (1997) Second-look laparotomy in advanced ovarian cancer: a critical assessment of morbidity and impact on survival. Ann Surg Oncol 4: 349–54CrossRefPubMedGoogle Scholar
  55. 55.
    Cacciari N, Zamagni C, Strocchi E et al. (1999) Advanced ovarian cancer patients with no evidence of disease after platinum-based chemotherapy: retrospective analysis of the role of second-look. Eur J Gynaecol Oncol 20: 56–60PubMedGoogle Scholar
  56. 56.
    Rubin SC, Randall TC, Armstrong KA et al. (1999) Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. Obstet Gynecol 93: 21–4CrossRefPubMedGoogle Scholar
  57. 57.
    Nicoletto MO, Tumolo S, Talamini R et al. (1997) Surgical second look in ovarian cancer: a randomized study in patients with laparoscopic complete remission—a Northeastern Oncology Cooperative Group-Ovarian Cancer Cooperative Group Study. J Clin Oncol 15: 994–9PubMedGoogle Scholar
  58. 58.
    Bookman MA, Greer BE, Ozols RF (2003) Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel versus cisplatin and paclitaxel (GOG158) and an update on GOG0182-ICON5. International Journal of Gynecological Cancer 13Suppl 2: 149–55PubMedGoogle Scholar
  59. 59.
    Ozols RF (2000) Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer. Semin Oncol 27: 3–7PubMedGoogle Scholar
  60. 60.
    (1995) NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. JAMA 273: 491–7Google Scholar
  61. 61.
    Morris M, Gershenson DM, Wharton JT et al. (1989) Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol Oncol 34: 334–8CrossRefPubMedGoogle Scholar
  62. 62.
    Eisenkop SM, Friedman RL, Spirtos NM (2000) The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 88: 144–53CrossRefPubMedGoogle Scholar
  63. 63.
    Segna RA, Dottino PR, Mandeli JP et al. (1993) Secondary cytoreduction for ovarian cancer following cisplatin therapy. J Clin Oncol 11: 434–9PubMedGoogle Scholar
  64. 64.
    Tay EH, Grant PT, Gebski V, Hacker NF (2002) Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Obstet Gynecol 99: 1008–13CrossRefPubMedGoogle Scholar
  65. 65.
    Zang RY, Zhang ZY, Li ZT, Chen J et al. (2000) Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer. J Surg Oncol 75: 24–30CrossRefPubMedGoogle Scholar
  66. 66.
    Scarabelli C, Gallo A, Carbone A (2001) Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol 83: 504–12CrossRefPubMedGoogle Scholar
  67. 67.
    Eisenkop SM (2004) Commenting on “future directions in the surgical management of ovarian cancer” by Berman 90: s35-39. Gynecol Oncol 94: 235–6PubMedGoogle Scholar
  68. 68.
    Markman M (2001) Intraperitoneal drug delivery of antineoplastics. Drugs 61: 1057–65CrossRefPubMedGoogle Scholar
  69. 69.
    Polyzos A, Tsavaris N, Kosmas C et al. (1999) A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer. Oncology 56: 291–6CrossRefPubMedGoogle Scholar
  70. 70.
    Barakat RR, Sabbatini P, Bhaskaran D et al. (2002) Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up. J Clin Oncol 20: 694–8CrossRefPubMedGoogle Scholar
  71. 71.
    Markman M, Bundy BN, Alberts DS et al. (2001) Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19: 1001–7PubMedGoogle Scholar
  72. 72.
    Armstrong DK, Bundy BN, Baergen R et al. (2002) Randomized phase III study of intravenous (IV) paclitaxel and cisplatin versus IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group trial (GOG 172). Pro Am Soc Clin Oncol abstr 803: 201Google Scholar
  73. 73.
    Plaisant N, Quenet F, Fabbro M et al. (2004) [Secondary debulking surgery and intraperitoneal chemotherapy in advanced or recurrent epithelial ovarian cancer]. Gynecol Obstet Fertil 32: 391–7CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag France 2006

Authors and Affiliations

  • P.-E. Colombo
  • P. Rouanet

There are no affiliations available

Personalised recommendations